Leuvectin Vical Inc.

Abstract

Vical's Leuvectin, a plasmid DNA expression vector encoding interleukin-2 (IL-2) complexed with a lipid delivery vehicle (DMRIE/DOPE)for intratumoral injection, is under development as a potential gene therapy for cancer. In 1997, it was in phase II trials for kidney and prostate cancer [249445], [270243]. In April 2001, the phase II trial in kidney cancer was discontinued, with a new phase II trial planned for this indication [406405]. In May 2001, prostate cancer trials were ongoing [409071]. By March 1999, testing for other indications had been suspended, with the company's priority being to work toward the most promising indications [316709]. In November 2000, it was announced that Vical has been issued US-06147055 for the use of gene-based, non-viral delivery of IL-2 for the treatment of cancer. The company was also issued US-05641665 covering the Leuvectin construct in 1997 [389677].

• Authors: A Kaushik
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 7 Pg. 976-81 (Jul 2001) ISSN: 1472-4472 [Print] England
• PMID: 11757801 (Publication Type: Journal Article, Review)

Chemical References

• 1,2-dioleoyl-glycero-3-phosphatidyl ethanolamine
• Drug Carriers
• Interleukin-2
• Lipids
• Phosphatidylethanolamines
• Quaternary Ammonium Compounds
• (3-dimyristyloxypropyl)(dimethyl)(hydroxyethyl)ammonium
• Prostate-Specific Antigen

Topics

• Animals
• Carcinoma, Renal Cell (immunology, therapy)
• Clinical Trials as Topic
• Cytotoxicity, Immunologic
• Drug Carriers
• Genetic Therapy (adverse effects)
• Genetic Vectors
• Humans
• Immunotherapy
• In Vitro Techniques
• Interleukin-2 (genetics, metabolism)
• Kidney Neoplasms (immunology, therapy)
• Lipids
• Male
• Phosphatidylethanolamines
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (immunology, therapy)
• Quaternary Ammonium Compounds
• Structure-Activity Relationship